International Journal of Drug Policy 52 (2018) 16–19 Contents lists available at ScienceDirect International Journal of Drug Policy journal homepage: www.elsevier.com/locat e/drugpo Short Report Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia a b b c Tamar Kikvidze , Niklas Luhmann , Elisabeth Avril , Maia Butsashvili , d b b a Konstantine Labartkava , Aurélie Etienne , Diane Le Pluart , Ina Inaridze , c a b, Ana Gamezardashvili , David Kharshiladze , Julie Bouscaillou Médecins du Monde Georgia, 46 Gutnis Street, Tbilisi, 0103, Georgia Médecins du Monde France, 62 rue Marcadet, 75018, Paris, France Clinic Neolab, 47 Tashkenti Street, Tbilisi, 0160, Georgia New Vector, 9 Mtskheta Street, Tbilisi, 0179, Georgia Background Sciences. The initial phase (2015–2016) of the NHCEP focused on providing 7000 free courses of Sofosbuvir (with Ribavirin+/ Eliminating hepatitis C PegInterferon) limited to persons with advanced liver ﬁbrosis (F3 or more corresponding to elastometry above 10 kPa or FIB4 > 3.25). The introduction of new highly effective direct-acting antiviral The ongoing second phase(2016–2020) intends totreateveryperson (DAA) therapies has created an opportunity for the global chronically infected with HCV (Gvinjilia et al., 2016). To succeed in elimination of hepatitis C
International Journal of Drug Policy – Elsevier
Published: Feb 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera